Key Takeaway: Precision BioSciences, a clinical stage gene editing company, has announced that it will report its fourth quarter and fiscal year 2025 results on March 12, 2026. The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies aimed at addressing high unmet medical needs. This financial update is anticipated by stakeholders.
Price reaction · baseline $4.92 (2026-03-09T16:14:00.000Z) · hit during market hours · 4 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-4.3%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is advancing its financial reporting.
The company is focused on developing therapies for unmet medical needs.
The use of the ARCUS platform highlights innovation in gene editing.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Mar. 9, 2026– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial
Frequently Asked Questions
When will Precision BioSciences report its Q4 results?
Precision BioSciences will report its fourth quarter results on March 12, 2026.
What platform does Precision BioSciences use?
The company utilizes its proprietary ARCUS platform for gene editing therapies.
What is the focus of Precision BioSciences?
Precision BioSciences focuses on developing therapies for high unmet medical needs.